---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-007636"
form_type: "8-K"
ticker: "OVID"
cik: "0001636651"
company_name: "Ovid Therapeutics Inc."
filed_at: "2023-03-13T23:59:59+00:00"
generated_at: "2026-06-18T04:29:57.556539+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ovid Therapeutics reports FY2022 net loss $54.2M; cash $129M; pipeline advancing

## Summary
- Net loss for FY2022 $54.2M ($0.77 per share) vs net income $122.8M ($1.78) in 2021, driven by prior Takeda milestone.
- Cash and equivalents $129.0M; expected to fund operations into first half of 2025.
- OV329 Phase 1 trial on track; full data with biomarker efficacy proxy expected H1 2024.
- Takeda reaffirms soticlestat regulatory filings in FY2024; Ovid eligible for up to $660M milestones plus royalties.
- Added epileptologist Manoj Malhotra and co-inventor Toshiya Nishi to leadership in Q1 2023.

## SEC filing metadata
- accession: 0001628280-23-007636
- form_type: 8-K
- ticker: OVID
- cik: 0001636651
- company_name: Ovid Therapeutics Inc.
- filed_at: 2023-03-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636651/000162828023007636/0001628280-23-007636-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636651/000162828023007636/ovid-20230313.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-007636
- JSON: https://secwatch.observer/filing/0001628280-23-007636.json
- Plain text: https://secwatch.observer/filing/0001628280-23-007636.txt

## Key facts
- Earnings Releases
  Ovid Therapeutics Inc. reported the fourth quarter and full year ended December 31, 2022 results: revenue $46,280 for the fourth quarter and $1.5 million for the year ended December 31, 2022.
  - Period: the fourth quarter and full year ended December 31, 2022
  - Revenue: $46,280 for the fourth quarter and $1.5 million for the year ended December 31, 2022
  - Result: reported results
  source text: Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636651/000162828023007636/0001628280-23-007636-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.